These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
760 related items for PubMed ID: 25277423
1. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness]. Basire A, Picard C. Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423 [Abstract] [Full Text] [Related]
2. [Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM]. Dettori I, Ladaique P. Transfus Clin Biol; 2014 Nov; 21(4-5):207-9. PubMed ID: 25267204 [Abstract] [Full Text] [Related]
3. Identification of anti-HPA-1a allo-antibodies using IgG platelet antibody detection and crossmatch system assay with Galileo Echo. Di Cristofaro J, Frassati C, Montagnie R, Basire A, Merieux Y, Picard C. Platelets; 2015 Nov; 26(5):421-4. PubMed ID: 25101933 [Abstract] [Full Text] [Related]
4. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness. Wang J, Xia W, Deng J, Xu X, Shao Y, Ding H, Chen Y, Liu J, Chen D, Ye X, Santoso S. Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675 [Abstract] [Full Text] [Related]
5. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients. Jia Y, Li W, Liu N, Zhang K, Gong Z, Li D, Wang L, Wang D, Jing Y, Wang J, Shan X. Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352 [Abstract] [Full Text] [Related]
6. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness. Brouk H, Bertrand G, Zitouni S, Djenouni A, Martageix C, Griffi F, Kaplan C, Ouelaa H. Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758 [Abstract] [Full Text] [Related]
7. Use of HLA- and HPA--matched platelets in alloimmunized patients. Kekomäki R. Vox Sang; 1998 Jun; 74 Suppl 2():359-63. PubMed ID: 9704468 [Abstract] [Full Text] [Related]
8. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children]. Pereira J, Bronfman L, Bertín P, Marzouka E, Hidalgo P, Amaya S, Mezzano D. Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051 [Abstract] [Full Text] [Related]
9. [Caracterization of HLA allo-immunization and clinical impact in transfusion and organ transplantation]. Delbos F, Cesbron A. Transfus Clin Biol; 2017 Sep; 24(3):131-137. PubMed ID: 28757117 [Abstract] [Full Text] [Related]
10. The mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness. Beligaswatte A, Tsiopelas E, Humphreys I, Bennett G, Robinson K, Davis K, Bardy P. Br J Haematol; 2013 Aug; 162(3):409-12. PubMed ID: 23651440 [Abstract] [Full Text] [Related]
11. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility. Fagundes IS, Franz JM, Jobim MS, Arend A, Merzoni J, Cardone JM, Gil B, Sekine L, Jobim LF. Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841 [Abstract] [Full Text] [Related]
12. Platelet antigens. The role of human platelet alloantigens (HPA) in blood transfusion and transplantation. Rozman P. Transpl Immunol; 2002 Aug; 10(2-3):165-81. PubMed ID: 12216947 [Abstract] [Full Text] [Related]